Orionis Biosciences B.V.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Chimeric Protein Comprising an Interferon Alpha 2MUTANT and a PD-L1 Binding Moiety (US 11,661,455) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 18, 2027The maintenance fee for Bi-Functional Chimeric Proteins and Uses Thereof (US 11,702,477) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Mar 12, 2027The maintenance fee for Therapeutic Targeting of Non-Cellular Structures (US 11,753,463) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Fibroblast Binding Agents and Use Thereof (US 11,896,643) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,702,477 | Bi-Functional Chimeric Proteins and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,988,538 | Bispecific Signaling Agents and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,384,154 | Targeted Chimeric Proteins and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,753,463 | Therapeutic Targeting of Non-Cellular Structures In force · High confidence | In force | High confidence | |
| US 11,084,859 | Targeted Mutant Interferon-Gamma and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,522,641 | Targeted Mutant Interferon-Gamma and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,661,455 | Chimeric Protein Comprising an Interferon Alpha 2MUTANT and a PD-L1 Binding Moiety In force · High confidence | In force | High confidence | |
| US 11,236,141 | Targeted Mutant Interferon-Beta and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,497,436 | Chimeric Protein, and Encoding Nucleic Acid Thereof, Comprising Interferon-Beta and a Targeting Moiety Comprising a Single-Domain Antibody or Single-Chain Antibody In force · Medium confidence | In force | Medium confidence | |
| US 11,001,631 | CLEC9A Binding Agents In force · High confidence | In force | High confidence |
Also on record, not counted in the 29: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
16 pending · 2 no status recorded